Nephros, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Nephros develops and sells water filtration products for medical and commercial markets. Figures below are in U.S. dollars; financial statement amounts are in millions unless noted.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Net revenue | $3.522 million | $3.697 million; down 4.7% |
| Gross profit / margin | $2.187 million / 62% | $2.111 million / 57% |
| Operating expenses | $2.387 million | $2.417 million |
| Operating loss | $0.200 million | $0.306 million |
| Net loss | $0.169 million; $0.02 per share | $0.306 million; $0.03 per share |
| Cash from operations | Use of $0.672 million | Source of $0.276 million |
| Cash and cash equivalents | $3.633 million at March 31, 2024 | $4.307 million at December 31, 2023 |
| Working capital | $6.201 million | $6.292 million at December 31, 2023 |
Gross margin improved by approximately five percentage points. Cash used in operations primarily reflected the quarterly loss, a $0.4 million inventory increase, and a $0.4 million decrease in accrued expenses, partly offset by higher accounts payable. Inventory rose to $2.779 million from $2.470 million. There were no investing cash flows; financing cash use was approximately $2,000.
Total liabilities were $3.236 million, including $1.709 million of lease liabilities. The filing reports no outstanding balance on the former secured note and no off-balance-sheet arrangements. Accumulated deficit was $144.6 million. Stockholders’ equity was $8.180 million.
Changes versus the prior comparable period
- Revenue declined mainly because unusually large emergency-response orders in Q1 2023 did not recur. Programmatic or recurring sales increased 12%, partly offsetting the decline.
- Gross margin increased from 57% to 62%, which management attributed to lower shipping costs and more favorable pricing terms with its largest supplier.
- SG&A rose 1% to $2.142 million, reflecting new CEO and CFO hires and sales-team expansion, partly offset by lower commissions and a one-time stock-compensation reversal.
- R&D expense fell 11% to $0.212 million, primarily following the 2023 wind-down of Specialty Renal Products (SRP).
- Cash from operations changed from a $0.276 million source to a $0.672 million use, reflecting inventory investment and accrued-expense payments.
Outlook, risks and notable items
- Management says existing cash is expected to fund the current operating plan for at least 12 months from issuance of the financial statements. This is an expectation, not a guarantee; weaker-than-expected results could require cuts to headcount, R&D, or other discretionary spending.
- No specific revenue or earnings guidance is provided. Management is focused on sales growth, expense control, and returning to positive operating cash flow; it says Q1 inventory investment is intended to support higher future volumes.
- Under the Medica license and supply agreement, the company has a 2024 minimum purchase obligation of €4.2 million (approximately $4.6 million); outstanding aggregate purchase commitments were €2.8 million (approximately $3.0 million) at March 31, 2024. The agreement term was extended through December 31, 2028.
- Customer concentration is material: Customer A generated 31% of Q1 revenue, versus 20% a year earlier. The three customers disclosed accounted for 40% of Q1 revenue; two customers represented 34% of receivables at quarter-end.
- Stock-option compensation included a net credit associated with reversal of expense for an immaterial prior-period forfeiture error, partly offset by current-period expense. Management also cited an approximately $75,000 one-time reversal in its SG&A discussion.
- Key risks include product acceptance and sales growth, reliance on suppliers and distributors, regulatory and product-liability exposure, competition, and potential need for additional capital. Management reported disclosure controls were effective and no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether recurring-sales growth continues and offsets the absence of unusually large emergency-response orders.
- Whether the improved gross margin is sustainable, including the effect of supplier pricing and shipping costs.
- Cash runway assumptions and the timing of inventory conversion, operating cash-flow improvement, and Medica purchase obligations.
- Exposure to major customers, particularly Customer A, and the effect of any change in their purchasing patterns or payment behavior.
- The nature and financial impact of the stock-compensation correction and reversal described in the filing.